Development of therapeutic drug for steatohepatitis by liver-specific bio-nanocapsules equipped with RNAi targeting TTC39B
Description: We developed a new steatohepatitis model by focusing on, a dietary oxidized cholesterol, 7-ketocholesterol (7KC). Administration of 7KC resulted in decrease in mitochondrial activity, modulation of autophagy mechanism, expression of inflammatory cytokines in obesity/diabetes model mice. Then, we reported that 7KC exacerbated lipid accumulation, inflammatory cell infiltration, and liver fibrosis (Frontier in Endocrinology 2020). In addition, we also succeeded in creating a “steatohepatitis-related cardiomyopathy” in a rodent NSH model (in submission). This is the first model showing NLRP3 inflammasome activation and cardiac dysfunction due to cholesterol accumulation in both the liver and heart.
Amount: ¥17,550,000
Funding type: research
Funder scheme: Grant-in-Aid for Scientific Research (B)
Start date: 2018-04-01
End date: 2021-03-31
Investigator: Masahiro Koseki
Institution: Osaka University
Funded outputs count: 17
Funder award ID: 18H03532
OpenAlex ID: G8966526734